clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - clopidogrel-hydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotische mittel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
lisinopril taw pharma 1 mg/ml lösung zum einnehmen
taw pharma (ireland) limited - lisinopril-dihydrat -
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - antithrombotische mittel - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segment elevation acute myocardial infarction, in kombination mit ass bei medizinisch behandelten patienten, für die eine thrombolytische therapie. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. weitere informationen finden sie in abschnitt 5.
lisinopril essential pharmaceuticals 1 mg/ml lösung zum einnehmen
essential pharma (m) - lisinopril dihydrat - lösung zum einnehmen - 1 mg/ml - lisinopril dihydrat 1.088 mg/ml - lisinopril
amlodipine essential pharmaceuticals 1 mg/ml suspension zum einnehmen
essential pharma (m) - amlodipine besilate - suspension zum einnehmen - 1 mg/ml - amlodipine besilate 1.386 mg/ml - amlodipine
vitawund 5,25 mg/g - salbe
gsk-gebro consumer healthcare gmbh - chlorhexidindigluconat - lebertransalben
stawodorm s
mr pharma gmbh (8024365) - diphenhydraminhydrochlorid - filmtablette - diphenhydraminhydrochlorid (01601) 50 milligramm
ropivacain readyfusor 2 mg/ml infusionslösung im applikationssystem
bioq pharma b.v. - ropivacainhydrochlorid monohydrat -
vitawund - wundpuder
novartis consumer health - gebro gmbh - chlorhexidin diacetat - biguanides and amidines
prostawern urtica kapseln
pharma wernigerode gmbh - brennnesselwurzel, te mit ethanol/ethanol-wasser (%-angaben) - kapsel - brennnesselwurzel, te mit ethanol/ethanol-wasser (%-angaben) 240.mg